“HHS can clearly insist on limiting the U.S. price of Xtandi to the median price for other large high-income countries,” said advocates, “particularly since the drug has already generated more than $10 billion in sales from Medicare alone based upon these unconscionable pricing disparities.”
“Cancer does not wait, nor should cancer patients have to wait for years for their government to act.”
That’s the message patient advocates reiterated in a Friday letter asking the Biden administration to help them secure a lifesaving prostate cancer drug that costs nearly $190,000 per year despite its development being 100% taxpayer-funded.
Last year, prostate cancer patient Eric Sawyer petitioned U.S. Health and Human Services (HHS) Secretary Xavier Becerra to grant march-in rights—under which the government can grant patent licenses to companies other than a drug’s manufacturer—for enzalutamide, which is sold under the brand name Xtandi. Continue reading